NEW YORK (GenomeWeb News) – Quintiles Transnational today said that it has acquired Targeted Molecular Diagnostics, a privately held lab focused on oncology testing using biomarker expression analysis technologies, for an undisclosed sum.
Quintiles said that the Westmont, Ill.-based lab will provide it with “strong capabilities in tissue-based testing.” It also said that TMD’s biomarker technology will help Quintiles’ customers gain a greater understanding of how their drugs work and which populations are most likely to benefit from their therapies.
“With the addition of TMD’s expertise, we can help customers develop novel, targeted cancer therapies and get them to market much faster by employing biomarkers in the development process,” King Jolly, senior vice president of drug development partnerships for NovaQuest, the managed partnership group of Quintiles.
TMD currently supports clinical trials being conducted in more than 40 countries, and it offers more than 100 biomarker assays, said Quintiles.